Pharma Industry News

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen will gain antibody technologies designed to discover and develop new molecules with broad applications across therapeutic areas

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]